Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lansoprazole: a comprehensive review

A E Zimmermann1, B G Katona

  • 1Astra Merck Inc., Baltimore, Maryland, USA.

Pharmacotherapy
|March 1, 1997
PubMed
Summary

Lansoprazole, a proton pump inhibitor, effectively treats ulcers and acid reflux. It demonstrates comparable or superior efficacy to other acid reducers like ranitidine and omeprazole, with a similar safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A review of omeprazole use in the treatment of acid-related disorders in children.

Clinical therapeutics·2001
Same author

The use of omeprazole in the pediatric population.

The Annals of pharmacotherapy·1998
Same author

Application of publication rates: another perspective.

Pharmacotherapy·1996
Same author

Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.

Pharmacotherapy·1995
Same author

Ceftriaxone-induced acute pancreatitis.

The Annals of pharmacotherapy·1993
Same author

Probable famotidine-induced thrombocytopenia.

DICP : the annals of pharmacotherapy·1991

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Lansoprazole is a substituted benzimidazole and a potent inhibitor of H+, K(+)-adenosine triphosphatase.
  • It is approved for treating various acid-related gastrointestinal disorders.

Purpose of the Study:

  • To evaluate the efficacy and safety of lansoprazole in treating duodenal ulcers, gastric ulcers, reflux esophagitis, and Zollinger-Ellison syndrome.
  • To compare lansoprazole with ranitidine, famotidine, and omeprazole for various gastrointestinal conditions.
  • To assess lansoprazole's role in Helicobacter pylori eradication when used with antibiotics.

Main Methods:

  • Clinical trials involving patients with duodenal/gastric ulcers, reflux esophagitis, Zollinger-Ellison syndrome, and H. pylori infections.
  • Comparative studies assessing healing rates, symptom relief, and adverse effects.
  • Dosage regimens included 30 mg/day for ulcers and esophagitis, and varying doses for Zollinger-Ellison syndrome.

Main Results:

  • Lansoprazole (30 mg/day) showed higher healing rates and faster symptom relief than ranitidine or famotidine for ulcers and esophagitis.
  • Compared to omeprazole (20 mg/day), lansoprazole provided faster pain relief, with equivalent healing rates.
  • Lansoprazole was superior to histamine2-receptor antagonists and similar to omeprazole for Zollinger-Ellison syndrome.
  • Combination therapy with lansoprazole or omeprazole and antibiotics achieved equivalent H. pylori eradication rates.
  • Lansoprazole was well-tolerated, with adverse effect rates comparable to ranitidine, famotidine, and omeprazole.

Conclusions:

  • Lansoprazole is an effective and well-tolerated treatment for various acid-related gastrointestinal conditions.
  • It offers comparable or superior efficacy to existing therapies, including omeprazole and histamine2-receptor antagonists.
  • Lansoprazole is a valuable therapeutic option for managing peptic ulcer disease, reflux esophagitis, and Zollinger-Ellison syndrome.

Related Experiment Videos